Ht-Logo-gigapixel-icon
Search
Close this search box.
Ht-Logo-gigapixel-icon
Search
Close this search box.
Friday, November 22, 2024
Canada’s Politics and Government News Source Since 1989
Latest Paper
Friday, November 22, 2024 | Latest Paper
Subscribe Now

TRENDING:

Nigel Rawson

Government hostility to biopharmaceutical industry reduces access to innovative drugs

  • Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need
Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023
If Canadians are not to endure further wait times and denials of access to innovative medicines, our governments need to change their antipathy towards the biopharmaceutical industry, write Nigel Rawson and John Adams. Image courtesy of Pixabay

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023
  • Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023
  • Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need
If Canadians are not to endure further wait times and denials of access to innovative medicines, our governments need to change their antipathy towards the biopharmaceutical industry, write Nigel Rawson and John Adams. Image courtesy of Pixabay

Government hostility to biopharmaceutical industry reduces access to innovative drugs

  • Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need
Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023
If Canadians are not to endure further wait times and denials of access to innovative medicines, our governments need to change their antipathy towards the biopharmaceutical industry, write Nigel Rawson and John Adams. Image courtesy of Pixabay

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023
  • Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need

Government hostility to biopharmaceutical industry reduces access to innovative drugs

Opinion | BY NIGEL RAWSON, JOHN ADAMS | November 15, 2023
  • Developers bring new drugs to Canada later than in other nations. Some aren’t launched here at all. The result is that Canadians who need
If Canadians are not to endure further wait times and denials of access to innovative medicines, our governments need to change their antipathy towards the biopharmaceutical industry, write Nigel Rawson and John Adams. Image courtesy of Pixabay

The PMPRB has outlived its usefulness

  • While patients would undoubtedly like lower drug prices, they don’t want PMPRB actions to lead to developers deciding not to launch new medicines in
Opinion | BY NIGEL RAWSON | June 26, 2023
Canadians with unmet health-care needs whose quality of life or longevity depends on access to new innovative medicines are the losers in this debacle, writes Nigel Rawson. Unsplash photograph by Towfiqu Barbhuiya

The PMPRB has outlived its usefulness

Opinion | BY NIGEL RAWSON | June 26, 2023
  • While patients would undoubtedly like lower drug prices, they don’t want PMPRB actions to lead to developers deciding not to launch new medicines in

The PMPRB has outlived its usefulness

Opinion | BY NIGEL RAWSON | June 26, 2023
  • While patients would undoubtedly like lower drug prices, they don’t want PMPRB actions to lead to developers deciding not to launch new medicines in
Canadians with unmet health-care needs whose quality of life or longevity depends on access to new innovative medicines are the losers in this debacle, writes Nigel Rawson. Unsplash photograph by Towfiqu Barbhuiya

Canadian pharmacy shelves could run out of crucial medicines due to U.S. laws

  • U.S. lawmakers in 16 states have introduced bills to facilitate wholesale importation of pharmaceutical products from Canada. Vermont actually has a law on the books and the
Opinion | BY NIGEL RAWSON | June 9, 2019
If importation of drugs into America from Canada were to proceed unchecked, Canadian prices would rise, writes Nigel Rawson. Photograph courtesy of Pixabay

Canadian pharmacy shelves could run out of crucial medicines due to U.S. laws

Opinion | BY NIGEL RAWSON | June 9, 2019
  • U.S. lawmakers in 16 states have introduced bills to facilitate wholesale importation of pharmaceutical products from Canada. Vermont actually has a law on the books and the

Canadian pharmacy shelves could run out of crucial medicines due to U.S. laws

Opinion | BY NIGEL RAWSON | June 9, 2019
  • U.S. lawmakers in 16 states have introduced bills to facilitate wholesale importation of pharmaceutical products from Canada. Vermont actually has a law on the books and the
If importation of drugs into America from Canada were to proceed unchecked, Canadian prices would rise, writes Nigel Rawson. Photograph courtesy of Pixabay
More Stories

News

Get free news updates

Opinion

Submit a guest opinion article

resources

Advertise

get help

Subscribe
CloseMenu